Synonyms: BS 194 | BS194 | compound 4k [PMID 21080703] [1]
Compound class:
Synthetic organic
Comment: BS-194 is reported as a potent, orally available inhibitor of cyclin-dependent protein kinases (CDKs) 1, 2, 7 and 9 [1].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
BS-194-induced CDK inhibition translates to antitumour effects in human tumour xenografts [1]. Reported off-targets include CAMKKβ, CK1, DYRK1A, ERK1, ERK2, and IRR which have IC50 values between 1-3.7μM [1]. We have tagged CDK2 as this compound's primary molecular target for data metrics purposes only. We fully acknowledge the multi-targeted nature of BS-194 and include additional kinase interactions in the table below. |
Selectivity at enzymes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|